Nextleaf Solutions CEO Paul Pedersen joined Steve Darling from Proactive to share news the company has added to their already impressive patent list with a U.S. Patent on the novel process for acetylating Cannabigerol and subsequent refinement of CBG-O-Acetate.
Pedersen shares more details about this patent and why they feel the CBG-derived prodrug produced under the patented process may hold significant potential as a therapeutic product based on research that CBG may be effective in the treatment of inflammation, pain, and nausea.